Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States by Adejumo, Adeyinka Charles et al.
© 2019 Hellenic Society of Gastroenterology www.annalsgastro.gr
 Annals of Gastroenterology (2019) 32, 504-513O R I G I N A L  A R T I C L E
Prevalence, trends, outcomes, and disparities in hospitalizations 
for nonalcoholic fatty liver disease in the United States
Adeyinka Charles Adejumoa,b,c,d, Gbeminiyi Olanrewaju Samuele, Oluwole Muyiwa Adegbalaf, 
Kelechi Lauretta Adejumod, Ogooluwa Ojelabic, Olalekan Akanbig, Olumuyiwa Akinbolaji Ogundipeh, 
Lydie Pania,b
North Shore Medical Center, Salem, MA; Tufts University Medical School, Boston, MA; University of Massachusetts 
Medical School, Worcester, MA; University of Massachusetts Lowell, MA; Englewood Hospital and Medical Center, NJ; 
University of Kentucky College of Medicine; St. Cloud State University, Plymouth, MN, USA
Abstract Background As the frequency of nonalcoholic fatty liver disease (NAFLD) continues to rise in 
the United States (US) community, more patients are hospitalized with NAFLD. However, data 
on the prevalence and outcomes of hospitalizations with NAFLD are lacking. We investigated the 
prevalence, trends and outcomes of NAFLD hospitalizations in the US.
Methods Hospitalizations with NAFLD were identified in the National Inpatient Sample 
(2007-2014) by their ICD-9-CM codes, and the prevalence and trends over an 8-year period 
were calculated among different demographic groups. After excluding other causes of liver 
disease among the NAFLD cohorts (n=210,660), the impact of sex, race and region on outcomes 
(mortality, discharge disposition, length of stay [LOS], and cost) were computed using generalized 
estimating equations (SAS 9.4).
Results Admissions with NAFLD tripled from 2007-2014 at an average rate of 79/100,000 
hospitalizations/year (P<0.0001), with a larger rate of increase among males vs. females 
(83/100,000  vs. 75/100,000), Hispanics vs. Whites vs. Blacks (107/100,000  vs. 80/100,000  vs. 
48/100,000), and government-insured or uninsured patients vs. privately-insured (94/100,000 vs. 
74/100,000). Males had higher mortality, LOS, and cost than females. Blacks had longer LOS and 
poorer discharge destination than Whites; while Hispanics and Asians incurred higher cost than 
Whites. Uninsured patients had higher mortality, longer LOS, and poorer discharge disposition 
than the privately-insured.
Conclusions Hospitalizations with NAFLD are rapidly increasing in the US, with a 
disproportionately higher burden among certain demographic groups. Measures are required to 
arrest this ominous trend and to eliminate the disparities in outcome among patients hospitalized 
with NAFLD.
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Introduction
With the increasing adoption of the Western diet and 
sedentary lifestyle, the prevalence of obesity, insulin resistance, 
type II diabetes, lipid disorders, and metabolic syndrome has been 
increasing [1-3]. Individuals with these disorders have a propensity 
to accumulate abnormal fat deposits in their liver; this is called 
nonalcoholic fatty liver disease (NAFLD). NAFLD is currently 
the most common liver disease and is estimated to affect 33% of 
adults worldwide (approx. 1 billion) [1]. NAFLD may progress 
to hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma [2-
4]. NAFLD represents a spectrum of liver diseases ranging from 
simple steatosis, steatohepatitis, to fibrosis and cirrhosis, with an 
increased risk for hepatocellular carcinoma. Clinical outcomes are 
poorer as patients’ progress from the benign end of the spectrum 
(steatosis) to the severe phenotypes [5-7].
Although studies have reported the rising prevalence of 
NAFLD in the community [8-10], the occurrence and burden 
among hospitalized patients have not been studied. Furthermore, 
gender, racial, socioeconomic, and regional disparities have 
been revealed in both prevalence and management outcomes 
for NAFLD-associated conditions [11,12]. However, no study 
has evaluated such disparities among patients hospitalized 
with NAFLD.
Considering the alarming increase in NAFLD and that 
end-stage liver disease from NAFLD is projected to be the 
number one reason for liver transplantation by 2020 [13], it 
is essential to evaluate the burden of and disparities among 
NAFLD-associated hospitalizations in the United States (US). 
This will allow early formulation of public health measures to 
quickly arrest any ominous trend. Therefore, we carried out 
this population-based study to investigate the prevalence and 
trends in the NAFLD in different demographic categories and 
the disparities among hospitalization outcomes of subjects 
admitted with NAFLD. We hypothesized that the prevalence 
and burden of NAFLD among hospitalized patients would be 
increasing, mirroring the pattern in the community.
Patients and methods
Data source
A retrospective cross-sectional analysis of the Healthcare 
Cost and Utilization Project Nationwide Inpatient Sample 
(HCUP-NIS) database was performed. The NIS is administered 
by the Agency for Healthcare Research and Quality, through a 
multi-stage clustered sampling by states, strata, and hospitals 
within the US for every year. Data from each year represent 20% 
of all the discharges across over 4500 non-federal community 
hospitals (public and academic centers) from about 40 states. 
Currently, 40 of 50 states in the US participate in the NIS. Each 
year of the NIS has about 7 million hospitalization records 
(weighted to 35 million hospitalizations) [14]. The NIS provides 
a fairly accurate representation of hospitalizations, because all 
the large and diverse states in the US participate in the program, 
including California, Florida, Texas, and New  York. In this 
study, we used data from the years 2007-2014 (n=61,324,882) 
that contained per discharge 15 procedures and about 25-30 
diagnoses all coded with the International Classification of 
Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes. 
Since the NIS is a completely de-identified publicly available 
data, no Institutional Review Board approval was required.
Study population and variables
After using the ICD-9-CM code of 571.8 to abstract records 
for patients aged 18 years and above with a discharge diagnosis of 
NAFLD (n=307,651, 0.009%), we eliminated records with other 
chronic liver disease—alcoholic liver disease, hemochromatosis, 
hepatitis C and B virus, primary biliary cirrhosis, autoimmune 
hepatitis, toxic liver disease, and other poorly defined liver 
diseases—and those with an organ transplant (Fig.  1 and 
Supplementary Table  1). The ICD-9-CM code for NAFLD has 
been used by many recent studies [15-20]. We also eliminated 
records with missing inputs, and abstracted demographic, patient, 
and hospital-related information. All the information used in 
this study either consisted of variables already available within 
the dataset or was created by us. We had 4 primary outcome 
variables: total hospital charge (THC; in US dollars), duration 
of hospitalization (length of stay in days: LOS), in-hospital 
mortality, and unfavorable disposition on discharge. For the THC 
we inflated the values before 2014 to the 2014 levels, using the 
Consumer Price Index from the US Bureau of Labor. Unfavorable 
disposition on discharge was derived from a multinomial variable 
in NIS to generate a binary variable: routine to home/home 
healthcare (as favorable) vs. transfer to another health facility 
(short-term acute hospital, skilled nursing, intermediate care, 
psychiatric, or rehabilitation centers) as unfavorable.
We collected demographic information on sex (male and 
female), race (Whites, Blacks, Hispanics, and others [Asian, 
Pacific Islanders, Native Americans, and others]), health 
insurance (government [Medicare, Medicaid], private, and 
others [self-pay, uninsured and other charges]), and median 
household income of residence zip-code (first to fourth 
quartile). We also extracted comorbid clinical conditions 
using the ICD-9-CM codes. Over 50 comorbid conditions 
were selected and combined to produce the Deyo-Charlson 
index, an extensively studied and widely used guide [21]. These 
comorbidities captured chronic diseases across all the systems 
in the body and have been used in many studies [22-26]. 
Furthermore, since the outcomes of liver diseases vary with the 
severity of liver injury, we stratified the NAFLD subjects into 
three, based on the Baveno IV consensus criteria: no cirrhosis, 
compensated cirrhosis, and decompensated cirrhosis [27]. 
Cirrhosis and its decompensation (hepatorenal syndrome, 
jaundice, hepatic encephalopathy, ascites, variceal bleeding, 
and portal hypertension) were identified through ICD-9-CM 
codes (Supplementary Table  1). The Baveno IV classification 
has been extensively used and validated in the HCUP-NIS for 
the reliable identification of liver cirrhosis and assessment of its 
severity [28]. Finally, hospital characteristics that could impact 
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outcomes were determined from the dataset and included 
hospital region (Northeast, South, Midwest and West), and 
hospital teaching status (rural, urban-nonteaching and urban-
teaching).
Statistical analysis
Analyses were performed using the Statistical Analysis 
System (SAS V.9.4, SAS Institute Inc., Cary, NC, US). In all 
Table 1 Characteristics of patients hospitalized with nonalcoholic fatty liver disease (NAFLD) in the US from 2007-2014 by sex
Characteristics Male n=83886 (~410054) Female n=126774 (~619253) P-value






Health Insurance, % <0.0001
Government 43.81 51.42
Private 43.84 39.12
Self-pay & others1 12.35 9.46
Income, % <0.0001
Lowest quartile 24.88 27.85
Second quartile 24.92 25.98
Third quartile 25.53 24.92






Hospital teaching status, % 0.0406
Rural 8.64 8.99
Urban non-teaching 42.89 42.23
Urban teaching 48.48 48.77
Charlson-Deyo comorbidity index, % <0.0001
Deyo: 0 32.45 32.56
Deyo: 1-3 47.56 50.40
Deyo: >3 19.99 17.04
Liver cirrhosis, % <0.0001
No cirrhosis 95.76 94.81
Compensated cirrhosis 1.93 2.39
Decompensated cirrhosis 2.31 2.80
In-hospital mortality, % 1.16 1.02 0.0033
Discharge disposition, % 0.0574
Home 88.16 87.86
Rehabilitation and acute care facility 11.84 12.14
LOS, days 4.75 4.55 <0.0001
THC, $ 47026.00 42848.00 <0.0001
1Self-pay & others: no charge, other government, Indian Health Service, Worker’s compensation, other miscellaneous 
LOS, length of stay in hospital; THC, total hospitalization cost
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the statistical models, a P-value of <0.05 was chosen a priori. 
We reported the effect estimates, P-values and 95% confidence 
intervals (CI), or the Bonferroni corrected P-values for 
multiple comparisons. Patients’ clinical characteristics 
were reported as mean and standard deviation (SD) for 
continuous variables with normal distributions, and as a 
median and inter-quartile range (IQR) for either continuous 
or counting variables without a normal distribution. Similarly, 
statistical tests were carried out using the chi-square test and 
percentages for the categorical variables, and Student’s t-test 
and the Wilcoxon test for numeric variables with normal 
and non-normal distributions, respectively. The trends 
were estimated using general linear models with NAFLD as 
outcome and year as a predictor. Other demographic factors 
were added to the model and their interaction with year was 
tested with a P-trend <0.01 set as significance. The adjusted 
odds ratio (AOR) was calculated with multivariate regressions 
using generalized estimating equations with the predictors 
(demographics, patient and hospital characteristics) and 
each of the 4 outcomes. Binary (mortality and discharge 
disposition), discrete numeric variables with over-dispersed 
count distributions (LOS), and continuous variables with 
a right-skewed spread (THC) were modeled with binary 
logistic, negative binomial and gamma functions, respectively. 
As recommended by HCUP, all analysis was performed 
with the STRATA, CLUSTER and WEIGHT for the 
SURVEYLOGISTIC, SURVEYFREQ and SURVEYMEANS 
procedures to account for the complex clustered sampling 
methodology [29]. For the GENMOD procedures, the CLASS, 
WEIGHT and REPEATED statements were used to account 
for these complex and in-hospital correlations [30].
Results
Baseline characteristics of patients hospitalized with 
NAFLD
The total of 210,660 hospitalized patients with NAFLD 
were more likely to be female (60.16% vs. 39.84%), with 
a similar mean age of 54 (Table  1). Compared to males, 
females were slightly less likely to be White (70.03% vs. 
73.51%) but more likely to be Black (9.56% vs. 7.67%) or 
Hispanic (15.06% vs. 12.94%). Females were more likely to 
be on governmental health insurance (51.42% vs. 43.81%) 
but less likely to be on private plans (39.12% vs. 43.84%) or 
uninsured (9.46% vs. 12.35%). They had a higher frequency 
of compensated (2.39% vs. 1.93%) and decompensated 
(2.80% vs. 2.31%) cirrhosis. The most common primary 
diagnoses during hospitalizations with NAFLD were morbid 
obesity, acute pancreatitis, and septicemia, in that order 
(Supplementary Table 2).
While the in-hospital mortality rate was lower among 
females (1.02% vs. 1.16%), the discharge disposition was 
similar across both sexes. The LOS was shorter (4.55  vs. 
4.75 days) and THC lower ($42,848.00 vs. $47,026.00) among 
females compared with males.
Predictors of inpatient mortality
Only increasing age, sex, health insurance, hospital region 
and teaching status, Charlson-Deyo comorbidity, and liver 
cirrhosis were significantly associated with mortality (Table 2). 
The odds of dying increased by 36% for every 10-year increase 
in age (AOR 1.36, 95%CI 1.31-1.42; P<0.0001), by 14% among 
individuals without health insurance/self-pay vs. those with 
private insurance (AOR 1.14, 95%CI 1.09-1.67; P=0.002). 
Mortality was also higher among NAFLD hospitalizations in 
urban centers vs. rural centers and for those with a higher 
comorbidity burden and liver cirrhosis. However, females had 
10% lower odds of mortality (AOR 0.91, 95%CI 0.83-0.99; 
P=0.03).
Predictors of discharge disposition
Significant predictors of unfavorable discharge disposition 
were age, race, health insurance, hospital region, and teaching 
status, comorbidity burden, and severity of cirrhosis (Table 2). 
There were 41% greater odds of unfavorable discharge for 
every 10-year increase in age. Unlike Blacks, who had 14% 
All records in the 2007-2014 HCUP-NIS data set (61,324,882)
Records with age <8 years (10,160,504)
All adult records (age ≥18 years) in 2007-2014 HCUP-NIS data
set (51,164,378)
All adult records with NAFLD (307,651)
Records without NAFLD (50,856,727)
Eliminated records (67,932)
● Alcoholic liver disease (4,582)
● Hemochromatosis (655)
● Hepatitis C virus disease (8,320)
● Hepatitis B virus disease (1,400)
● Primary biliary cirrhosis (353)
● Autoimmune hepatitis (586)
● Toxic liver disease (1)
● Previous organ donor (1)
● Other poorly specified liver diseases (38,390)
● Previous organ recipient (1,544)
All adult records with NAFLD (239,719)
Records with missing inputs (29,059)
Complete adult records with NAFLD (210,660)
Figure 1 Selection flowchart for patients hospitalized for nonalcoholic 
fatty liver disease (NAFLD) in the Healthcare Cost and Utilization 
Project Nationwide Inpatient Sample (HCUP-NIS) data 2007-2014
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greater odds of unfavorable discharge compared with Whites 
(AOR 1.14, 95%CI 1.06-1.22; P<0.0001), Hispanics and Asians 
had 29% and 11% lower odds, respectively (AOR 0.71, 95%CI 
0.66-0.76; P<0.0001 and AOR 0.89, 95%CI 0.81-0.98; P=0.008). 
Compared to the privately insured, inpatients with government 
insurance and those who were uninsured/self-pay had 90% and 
24% higher odds, respectively, of unfavorable discharge (AOR 
1.90, 95%CI 1.81-2.00; P<0.0001 and AOR 1.24, 95%CI 1.14-
1.34; P<0.0001). Compared to the Northeast, the Southern 
and Western regions of the US had lower odds of unfavorable 
discharges.
Predictors of LOS
Sex, age, Black race, health insurance, hospital region and 
teaching status, comorbidity burden, and liver cirrhosis were 
associated with LOS (Table 3). Females had a 5% shorter LOS 
than males (4.35 [95%CI, 4.26-4.45] vs. 4.18 [95%CI 4.08-4.27] 
days; P<0.0001) (Table 3). Unlike other races, when compared 
to Whites, Blacks had a 7% longer LOS (4.48 [95%CI 4.34-4.62] 
vs. 4.20 [95%CI 4.11-4.29] days; P<0.0001). Government-
insured and uninsured/self-pay patients had 19% and 10% 
longer stays, respectively (4.65 [95%CI 4.56-4.75] and 4.28 
[95%CI 4.14-4.42] vs. 3.90 [95%CI 3.81-3.99] days; P<0.0001). 
Individuals in the lowest and second quartile had 4% and 3% 
longer LOS, respectively, compared to those from the highest 
income quartile. Compared to inpatients in the Northeastern 
regions, those in the Midwest and West had 5% and 7% shorter 
LOS (4.20 [95%CI 4.10-4.36] and 4.11 [95%CI 3.99-4.23] 
vs. 4.40 [95%CI 4.27-4.54] days; P=0.0385 and P=0.001, 
respectively). NAFLD hospitalizations in urban centers and 
those with higher comorbidity indices were associated with a 
longer LOS (Table 3).
Table 2 Determinants of in-hospital mortality and discharge disposition of patients hospitalized with nonalcoholic fatty liver disease (NAFLD)
Characteristics In-hospital mortality Discharge disposition
aOR LCL UCL P-value aOR LCL UCL P-value
Age Per 10 year increase 1.36 1.31 1.42 <0.0001 1.41 1.39 1.43 <0.0001
Sex Female vs. male 0.91 0.83 0.99 0.0291 1.00 0.97 1.03 0.7793
Race
Black vs. White 1.02 0.83 1.25 1 1.14 1.06 1.22 <0.0001
Hispanics vs. White 0.84 0.69 1.03 0.134 0.71 0.66 0.76 <0.0001
Asians & others vs. White 0.99 0.78 1.25 1 0.89 0.81 0.98 0.0082
Health insurance
Government vs. private 1.02 1.00 1.30 0.061 1.90 1.81 2.00 <0.0001
Self-pay & others1 vs. private 1.14 1.09 1.67 0.002 1.24 1.14 1.34 <0.0001
Income status
Lowest vs. highest quartile 1.18 0.99 1.41 0.0857 1.04 0.97 1.12 0.8205
Second vs. highest quartile 1.10 0.92 1.30 0.9122 1.03 0.96 1.10 >0.99
Third vs. highest quartile 1.11 0.94 1.31 0.6283 1.03 0.96 1.09 >0.99
Hospital region
Midwest vs. Northeast 1.18 0.96 1.45 0.2286 0.99 0.91 1.09 >0.99
South vs. Northeast 1.22 1.01 1.48 0.0266 0.80 0.74 0.87 <0.0001
West vs. Northeast 1.41 1.15 1.73 <0.0001 0.90 0.83 0.98 0.0102
Hospital teaching status
Urban non-teaching vs. rural 1.16 0.93 1.44 0.33 0.90 0.83 0.97 0.0039
Urban teaching vs. rural 1.42 1.14 1.76 0.0003 0.83 0.77 0.90 <0.0001
Charlson-Deyo comorbidity index
Deyo: 1-3 vs. 0 2.34 1.93 2.84 <0.0001 1.39 1.33 1.46 <0.0001
Deyo: >3 vs. 1-3 7.56 6.15 9.28 <0.0001 2.25 2.12 2.39 <0.0001
Liver cirrhosis
Compensated vs. no-cirrhosis 2.34 1.93 2.84 <0.0001 1.18 1.07 1.30 0.0001
Decompensated vs. no-cirrhosis 7.56 6.15 9.28 <0.0001 1.19 1.09 1.31 <0.0001
1Self-pay & others: no charge, other government, Indian Health Service, Worker’s compensation, other miscellaneous
aOR, adjusted odds ratio; LCL, lower confidence limit; UCL, upper confidence limit
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Predictors of THC
Male sex, Hispanic and Asian races, hospital region and 
teaching status, and comorbidity burden were associated with a 
higher THC among inpatients with NAFLD (Table 3). Females 
had 7% lower THC than males ($35,662 [95%CI 34,349-
37,026] vs. $38,299 [95%CI 36,872-39,7768]; P<0.0001). While 
Blacks ($35,850 [95%CI 34,290-37,482]) showed no difference 
in THC compared to Whites ($35,267 [95%CI 33,905-36,684]; 
P>0.99), Hispanics and Asians had a 9% higher THC ($38,397 
[95%CI 36,812-40,049]; P<0.0001 and $38,414 [95%CI 36,485-
40,445]; P=0.0005). Inpatients in the Western regions ($49,304 
[95%CI 46,970-51,755]) had 42% higher THC compared to 
the Northeastern regions ($34,795 [95%CI 32,502-37,249]; 
P<0.0001), unlike those in the Midwest ($31,244 [95%CI 
29,647-32,927]; P=0.022) and the South ($34,795 [95%CI 
32,502-37,249]; P>0.99). Urban centers (non-teaching and 
teaching) had a higher THC compared to rural centers ($41,177 
[95%CI 39,463-42,965] and $47,298 [95%CI 45,139-49,560] 
vs. $25,911 [95%CI 24,551-27,348]; P<0.0001). THC increased 
with the number of comorbidities (Table 3).
Trends in hospitalizations for NAFLD
Hospitalizations with NAFLD almost tripled, with an increase 
of 79 NAFLD diagnoses per 100,000 hospitalizations per year, 
from 319/100,000 in 2007 to 902/100,000 hospitalizations in 2014 
(Fig. 2A, Supplementary Table 3). All through the study period, 
males had both a higher frequency of NAFLD and a slightly 
steeper increase in the frequency of NAFLD hospitalization 
per year (83 vs. 76 per 100,000 hospitalizations, P<0.0001) (see 
slopes in Fig. 2B). After the trend was stratified by race, Hispanics 
had the highest prevalence of NAFLD hospitalizations, followed 
Table 3 Determinants of total cost and duration of hospitalization of patients admitted with nonalcoholic fatty liver disease (NAFLD)
Characteristics Hospital charges Length of stay
aMR LCL UCL P-value aMR LCL UCL P-value
Age Per 10 year increase 1.02 1.01 1.02 <0.0001 1.01 1.01 1.02 <0.0001
Sex Female vs. male 0.93 0.92 0.94 <0.0001 0.96 0.95 0.97 <0.0001
Race  
Black vs. White 1.00 0.94 1.07 1 1.07 1.04 1.10 <0.0001
Hispanics vs. White 1.09 1.04 1.14 <0.0001 0.98 0.95 1.00 0.1119
Asians & others vs. White 1.09 1.03 1.15 0.0005 1.02 0.99 1.06 0.437
Health insurance
Government vs. private 1.01 0.99 1.03 1 1.19 1.17 1.22 <0.0001
Self-pay & others1 vs. private 0.97 0.94 1.00 0.0379 1.10 1.06 1.13 <0.0001
Income status
Lowest vs. highest quartile 0.98 0.93 1.04 1 1.04 1.01 1.07 0.0028
Second vs. highest quartile 0.99 0.94 1.05 1 1.03 1.00 1.06 0.0163
Third vs. highest quartile 1.00 0.96 1.05 1 1.02 0.99 1.04 0.5198
Hospital region
Midwest vs. Northeast 0.90 0.81 0.99 0.0219 0.95 0.91 1.00 0.0385
South vs. Northeast 1.00 0.91 1.10 1 0.99 0.95 1.03 >0.99
West vs. Northeast 1.42 1.29 1.56 <0.0001 0.93 0.89 0.98 0.0009
Hospital teaching status
Urban non-teaching vs. rural 1.59 1.49 1.70 <0.0001 1.13 1.09 1.17 <0.0001
Urban teaching vs. rural 1.83 1.70 1.96 <0.0001 1.23 1.19 1.27 <0.0001
Charleson-Deyo comorbidity index
Deyo: 1-3 vs. 0 1.12 1.10 1.14 <0.0001 1.14 1.12 1.16 <0.0001
Deyo: >3 vs. 1-3 1.49 1.45 1.54 <0.0001 1.55 1.51 1.59 <0.0001
Liver cirrhosis
Compensated- vs. no-cirrhosis 0.97 0.90 1.03 0.5822 0.97 0.92 1.01 0.1787
Decompensated- vs. no-cirrhosis 0.76 0.72 0.81 <0.0001 0.83 0.79 0.86 <0.0001
1Self-pay & others: no charge, other government, Indian Health Service, Worker’s compensation, other miscellaneous
aMR, adjusted mean ratio; LCL, lower confidence limit; UCL, upper confidence limit
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by Whites, slightly higher than Asians, while Blacks had the 
lowest prevalence. The rate of NAFLD hospitalizations per 
year followed a similar trend, with Hispanics having an average 
of 107 new cases of NAFLD per 100,000 hospitalizations per 
year compared to 48 in Blacks, and to 79.5 and 80.4 in Whites 
and Asians (see slopes in Fig.  2C). Privately-insured and 
uninsured individuals had a higher rate and trend of NAFLD 
hospitalizations than those with government insurance (see 
slopes in Fig. 2D). There was no statistically significant difference 
in the frequency and trends of hospitalizations for NAFLD 
(Fig. 2E). Finally, there was a regional trend in the frequencies of 
NAFLD hospitalizations (see trends and slopes in Fig. 2F), with 
the Western region having the highest frequencies and rate of 
increase in NAFLD hospitalizations (90.26/100,000), followed 
by the South (81.10/100,000), then the Midwest (74.58/100,000), 
with the least being in the Northeastern region (67.92/100,000). 
The graph (Fig. 2F) reveals that the Western regions of the US 
have both a higher burden of NAFLD among hospitalizations 
and a sharper increase in this burden per year.
Discussion
In this nationally representative study, we showed that the 
frequency of NAFLD among hospitalized patients tripled from 
Trends in hospitalizations for NAFLD in the US Trends in hospitalizations for NAFLD stratified by sex
Trends in hospitalizations for NAFLD stratified by race
Trends in hospitalizations for NAFLD stratified by income quartile Trends in hospitalizations for NAFLD stratified by
geographic region
Trends in hospitalizations for NAFLD stratified
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2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
y = 79.012x - 158246
R2 = 0.9947
y = 79.456x - 159110
R2 = 0.9926
y = 48.339x - 96791
R2 = 0.9723
y = 94.101x - 188383
R2 = 0.9889
y = 94.431x - 189060
R2 = 0.9789
y = 73.569x - 147427
R2 = 0.9922
y = 80.799x - 161885
R2 = 0.995
y = 81.098x - 162404
R2 = 0.994
y = 74.581x - 149384
R2 = 0.9684
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y = 90.261x - 180768
R2 = 0.9866
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R2 = 0.9929
Figure 2 Trends in hospitalizations for nonalcoholic fatty liver disease (NAFLD) in the US from 2007-2014 (A), and categorized by sex (B), race 
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2007-2014, and that this increase varied significantly across 
demographic groups. Males, Hispanics, individuals with non-
private health insurance, and those residing in the Western and 
Southern regions of the US were disproportionately affected, 
with a higher prevalence of NAFLD and poorer outcomes.
More than 60% of the patients in our study were female, 
suggesting that primary admissions for NAFLD were more 
burdensome among women; however, the HCUP-NIS had more 
female hospitalizations (female 59.73% vs. male 40.27%) before 
selecting for NAFLD. In contrast, there was a higher frequency 
of NAFLD hospitalizations among men than women (Fig. 2A), 
consistent with many studies showing that both NAFLD and 
nonalcoholic steatohepatitis are more prevalent among males than 
females [8,31-36]. We extend these studies in many ways. First, 
we reported that the male-predominant distribution of NAFLD 
observed in the community continues to the hospital setting. 
Second, we showed that males also had a higher rate of NAFLD 
hospitalization per year than women, further widening the gap in 
the burden of NAFLD between the sexes. The higher prevalence 
of NAFLD among males has been attributed to higher frequencies 
of insulin resistance and greater consumption of alcohol and 
non-diet soda among males compared to females [37]. Third, 
we showed that males have poorer in-hospital outcomes among 
NAFLD subjects: higher mortality, greater THC, and longer 
LOS. The cause of these poorer indexes among males may be 
related to health-seeking attitudes. Women utilize primary care 
more frequently [38-40], and may have had better management 
of their comorbidities, resulting in less severe presentations on 
admissions [41]. In addition, our data suggest that males have 
more comorbidities with a Charlson-Deyo score >3 (male 19.99% 
vs. female 17.04%). To curtail these poor trends among males, 
public health studies of optimal measures should be instituted, 
targeted towards encouraging better control of comorbidities in 
males in the community.
We also report that hospitalization for NAFLD was higher 
among Hispanics than in other racial groups (Fig. 2B), consistent 
with many studies [42-44]. As with the sexual disparities 
mentioned above, our findings extend these studies in many ways 
[42,43]. We demonstrated that a similar Hispanic-predominant 
distribution of NAFLD occurs among hospitalized patients and 
that Hispanics show a greater increase in the rate of NAFLD 
hospitalizations than other races, suggesting that an epidemic 
of NAFLD among the Hispanic population of the US might be 
imminent. The higher prevalence of NAFLD among Hispanics 
is an active focus for research [44]. Racial/ethnic variation in 
NAFLD prevalence has been partly attributed to diet, lifestyle, 
and genetic differences. One of the most studied genes is the 
Patatin-like phospholipase domain-containing protein 3 (PNPLA3) 
which encodes a membrane-bound phospholipase protein that 
regulates energy storage and usage. Hispanics have an allele of 
PNPLA3 (rs738409[G]) that favors increased fat accumulation 
in the liver, unlike Blacks who have a different allele of PNPLA3 
(rs6006460[T]) that results in lower hepatic fat content [5,45]. 
Furthermore, Hispanics and Asians had a higher cost but better 
discharge disposition outcomes. The higher cost corroborates 
other studies by revealing the escalating cost of healthcare among 
Hispanics, who tend to use emergency departments more than 
office visits and therefore do not benefit from the preventive 
medical services prioritized by primary care physicians. The better 
discharge dispositions among Hispanics and Asians with NAFLD 
compared to Whites mirror other diseases. The causes remain 
unclear [46,47], but may be related to the availability of support 
at home, financial resources or the ethnic beliefs of patients 
and their families. Hispanic culture treats elders with respect 
and views discharge to home as a more positive outcome [48]. 
Similarly to reports from other studies on blacks, we showed that 
they had a longer LOS and poorer discharge disposition, which 
might be related to their higher comorbidity burden [49,50]. On 
further analysis, our results showed that Blacks had the highest 
frequency of comorbidities (Deyo ≥1:  71.8%) vs. other races: 
Whites (68.34%), Hispanics (60.87%), and Asians and other races 
(65.4%). To slow down this increasing burden of NAFLD among 
Hispanics, aggressive public health measures are needed, directed 
at Hispanic-specific risk factors such as diet, lifestyle, and health-
seeking behaviors. More importantly, public health outreaches 
should be performed within the Hispanic community, to sensitize 
Hispanics to their higher susceptibility to NAFLD. Furthermore, 
primary care physicians could have a higher suspicion of NAFLD 
among their Hispanic and White patients.
Health insurance determines the type of healthcare available 
to the holder. Our data reports higher odds of mortality, poorer 
discharge disposition, and longer LOS among other groups 
compared to the privately-insured. Our results are similar to those 
of studies in 1993 and 2009, which showed that the uninsured 
population has higher mortality than the insured among 
community dwellers in the US [51,52]. Findings from another study 
among patients hospitalized in the US for myocardial infarction, 
stroke, and pneumonia are also consistent with our study [53]. 
These outcome disparities have been attributed to numerous 
factors, including difficulty in arranging discharge disposition, 
poor or absent outpatient management of comorbidities, lack of 
a primary care physician, less frequent use of subspecialists, and 
lower use of invasive and expensive procedures, amongst others 
[53,54]. We also demonstrated higher hospitalization rates and 
a greater number of hospitalizations/year among government-
insured and uninsured/self-pay vs. privately-insured, implying 
that the causes of higher hospitalizations among the non-privately 
insured persist in the US and continue to widen the gap between 
privately and non-privately insured patients.
Our study observed significant variations in prevalence 
rate and yearly increase in NAFLD within the geographic 
distribution of the US. Interestingly, our observations follow 
the geographic trends in obesity and type 2 diabetes mellitus 
within the US, which are both risk factors for NAFLD [55]. 
Similar geographic distributions have been reported for race, 
income, and health insurance types [56]. Trending from 
Northeast to Midwest, to West and South regions of the US, 
there is generally higher proportion of ethnic minorities with 
fewer personal resources, poorer access to healthcare and 
fewer high-quality healthcare facilities, which might all be 
responsible for the higher prevalence and mortality among 
hospitalizations with NAFLD [56]. Furthermore, these regional 
disparities could reflect systematic problems at different levels 
of healthcare delivery, and they warrant further investigations.
Our study should be interpreted cautiously, bearing in mind 
the limitations of a cross-sectional study in general and those 
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of ICD-9 coding in particular. There may have been coding 
errors and imprecision in the ICD-9 implementation, resulting 
in underestimation of the cases. The NIS does not contain 
information on how NAFLD was diagnosed, including magnetic 
resonance imaging, liver biopsy, ultrasound, and liver function 
tests. Furthermore, we were unable to confirm the diagnosis by 
requesting the records, as the NIS is completely de-identified. 
The prevalence of NAFLD can differ significantly based on the 
diagnostic modality, and this might have affected our results. 
Furthermore, the difference in diagnostic modalities may 
contribute to variations in prevalence of NAFLD across income 
and region categories in our study. However, because physicians 
and centers in the US comply with similar practice guidelines, 
we do not expect significant regional variations in the diagnostic 
modalities of choice for NAFLD. The absence of laboratory 
data made it impossible to calculate the model for end-stage 
liver disease score and other indices of liver severity. However, 
we used the Charlson-Deyo and Baveno IV indexes, which are 
well-researched parameters, to account respectively for various 
non-hepatic and hepatic-specific comorbidities. Although these 
comorbidities were captured in ICD-9-CM, it does not capture 
the severity of each illness. Very few individuals from other races 
were in the NIS dataset, so we could not investigate the presence 
of disparities among those groups. Although NAFLD is a 
spectrum of liver disease with different outcomes, unfortunately 
the ICD-9-CM nomenclature does not distinguish among the 
subtypes, so we were unable to study how they vary with sex and 
race. Furthermore, the NIS does not specify the immediate cause 
of death, thus making it impossible for us to study the possible 
factors responsible for the higher death rate among males and 
the uninsured population. Despite these shortcomings, we 
believe that since the NIS encompasses numerous hospitals 
across various states in the US, it provides an excellent nationally 
representative sample and results in reliable estimates.
In conclusion, our novel findings revealed a rising 
frequency of hospitalizations for NAFLD in the US. There are 
demographic and regional variations in the trends and clinical 
outcomes of hospitalizations with NAFLD from 2007-2014 in 
the US among males, Hispanics, Blacks, non-privately insured, 
and individuals in the Southern and Western regions of the 
US. Systemic factors at multiple levels of healthcare perpetuate 
these inequalities. Future studies are needed to identify and 
eliminate these inequalities, and aggressive public health 
measures are required to arrest this increasing trend in NAFLD.
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Supplementary Table 1 ICD-9-CM codes used to identify clinical conditions in the study
Clinical condition ICD-9-CM codes
NAFLD 571.8
Alcoholic liver disease 571.1, 571.2
Hemochromatosis 275.01, 275.02, 275.03
Hepatitis C virus 070.41, 070.44, 070.51, 070.54, 070.7x
Hepatitis B virus 070.2x, 070.3x
Primary biliary cirrhosis 571.6
Autoimmune hepatitis 571.42
Alcohol use 303.x, 305.0x
Toxic liver disease 571.41
Previous organ donor V59.9
Other poorly specified liver disease 57.20, 57.21, 57.38, 789.59, 790.4, 790.5, 794.8
Previous organ recipient V42
Charleson-Deyo comorbidity Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM 
and ICD-10 administrative data. Med Care 2005;43:1130-1139.
Cirrhosis 571.2, 571.5, 571.6
Ascites 789.5





NAFLD, nonalcoholic fatty liver disease
Supplementary Table 2 Ten most common primary diagnoses during hospitalizations with nonalcoholic fatty liver disease (NAFLD)
Primary diagnosis during admissions with NAFLD Percentage
1 Morbid obesity 8.18
2 Acute pancreatitis 5.76
3 Septicemia 2.80
4 Cholelithiasis with acute cholecystitis 2.45
5 Diverticulitis without hemorrhage 2.42
6 Pneumonia 2.06
7 Chest pain 1.61
8 Acute renal failure 1.44
9 Hepatic coma 1.41
10 Noninfectious gastroenteritis 1.24
Supplementary Table 3 Trends in hospitalizations for nonalcoholic fatty liver disease (NAFLD): Crude (A), by Sex (B), Race (C), Health 
Insurance (D), Income status (E) and Region (F)



















C Year Race Hispanic Asian & others
White Black
2007 345.2138078 211.5528 429.6544736 301.2815626
2008 439.2765342 303.8477801 559.9318419 390.7543265
2009 530.4674604 322.4453688 623.4412678 465.7056005
2010 618.6889257 357.218618 764.9540633 537.7233048
2011 666.2354542 403.1359322 954.987282 585.0501065
2012 740.7396666 467.7050265 949.4851777 692.1192444
2013 814.0259157 490.3650287 1053.124697 757.4262049
2014 934.099089 589.5746979 1194.72306 900.1745219
D Year Health insurance
Government Private Uninsured
2007 233.6445664 445.541355 410.4147548
2008 295.5638706 590.0811364 568.6565458
2009 375.838597 679.1373568 681.6099381
2010 452.4974872 791.9016497 739.8659875
2011 515.5626597 858.4872582 889.3634916
2012 579.1305248 929.4504297 945.2226749
2013 644.4702578 1012.832035 1026.869551
2014 771.1176676 1156.003214 1081.955946
(Contd...)
E Year Income quartile
Lowest quartile Second quartile Third quartile Highest quartile
2007 287.3065702 314.7324152 349.2508911 335.2828222
2008 367.9335575 411.602361 446.112562 449.1031602
2009 430.7485217 487.3407596 559.4463107 545.2464027
2010 507.685615 584.7933847 614.3664455 654.3592592
2011 607.2054873 642.9025556 686.785994 669.7832124
2012 674.4647119 703.8829285 753.3572514 736.4645929
2013 746.157853 783.8542643 817.9677597 799.1685988
2014 868.0680106 903.9591296 921.796328 931.9530444
F Year Hospital region
Northeast Midwest South West
2007 274.2737481 281.9182085 348.6454802 351.9857538
2008 364.1914139 364.6546297 438.2644351 491.0300817
2009 379.0960492 489.3696665 522.2464921 588.1702636
2010 441.8142168 538.4424227 637.8965765 667.0421232
2011 511.6211456 622.333144 673.136137 779.0749918
2012 610.0322824 628.9297393 761.270189 821.2890235
2013 664.8328239 708.962684 833.861041 892.8920795
2014 765.6523808 859.1639451 931.7766417 1032.166712
Rates are per 100,000 hospitalizations
Supplementary Table 3 (Continued)
